GTC Biotherapeutics - GTC Biotherapeutics in the News


	2009 PRESS RELEASE ARCHIVE November 19, 2009 - GTC Biotherapeutics Receives Extension to Regain Compliance with NASDAQ Listing Standards November 6, 2009 - GTC Biotherapeutics Reports Third Quarter 2009 Financial Results November 2, 2009 - LFB Provides $10 Million of Funding to GTC Biotherapeutics - LFB Converts Preferred Stock to Common Shares October 5, 2009 - GTC Biotherapeutics Announces Changes in Board September 18, 2009 - GTC Biotherapeutics Receives NASDAQ Notice; Intends to Request Hearing September 14, 2009 - GTC Biotherapeutics Named in Annual Wall Street Journal Technology Innovation Awards July 31, 2009 - GTC Biotherapeutics Reports Second Quarter 2009 Financial Results July 24, 2009 - GTC Biotherapeutics to Host Second Quarter 2009 Earnings Call and Webcast on Friday, July 31, 2009 July 8, 2009 - GTC Biotherapeutics In-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals June 19, 2009 - GTC Biotherapeutics Receives Notice Related to NASDAQ Minimum Market Value Rule June 18, 2009 - GTC Biotherapeutics Enters Agreements with LFB for Funding of $12.3 Million with an Option For LFB to Fund an Additional $6.4 Million May 26, 2009 - GTC Biotherapeutics Announces One-for-Ten Reverse Stock Split May 22, 2009 - GTC Biotherapeutics to Webcast Annual Meeting, May 27th, 2009 May 13, 2009 - GTC Biotherapeutics Reports First Quarter 2009 Financial Results May 12, 2009 - GTC Biotherapeutics Regains Compliance with NASDAQ Marketplace Rule 5550 May 7, 2009 - GTC Biotherapeutics to Host First Quarter 2009 Earnings Call and Webcast, Wednesday, May 13, 2009 May 6, 2009 - GTC Biotherapeutics Reports Launch of ATryn® in the U.S. by Lundbeck Inc. May 6, 2009 - ATryn Available for Patients with Hereditary Antithrombin Deficiency, a Rare Blood Clotting Disorder March 30, 2009 - GTC Biotherapeutics Reports Progress in Preparations to Launch ATryn® in the U.S. March 19, 2009 - GTC Biotherapeutics Receives Notice Related to NASDAQ Minimum Market Value Rule March 13, 2009 - GTC Biotherapeutics Provides Update on Agreement with LEO Pharma A/S March 9, 2009 - GTC Biotherapeutics Reports Progress in ATryn® Program in U.S. February 27, 2009 - GTC Biotherapeutics Reports Fourth Quarter and Year End 2008 Financial Results February 26, 2009 - GTC Biotherapeutics Enters Follow-On Biologic Founder Development Collaboration with AgResearch February 23, 2009 - GTC Biotherapeutics to Host Fourth Quarter and Year End 2008 Earnings Call and Webcast on Friday, February 27, 2009 February 23, 2009 - GTC Biotherapeutics Licenses JCOM to Develop Recombinant Human Insulin Products for Asia February 6, 2009 - ATryn® (Antithrombin [Recombinant]) Approved by the FDA - Only recombinant option for patients with hereditary antithrombin deficiency, a rare and potentially life-threatening condition February 3, 2009 - GTC Biotherapeutics to Webcast Corporate Presentation at the 11th Annual BIO CEO & Investor Conference January 21, 2009 - GTC Regains Compliance with NASDAQ Marketplace Rule 4310 January 9, 2009 - FDA Advisory Committee Recommends GTC Biotherapeutics' ATryn* (antithrombin [Recombinant]) - If approved, ATryn will be first recombinant human antithrombin available in the U.S.¹
	Copyright 2009 GTC Biotherapeutics, All Rights Reserved